Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes

doi:10.4239/wjd.v14.i8.1146

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9363)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

237

WORD

HTML

5282

Figures (1-3)

712

Sum=6267

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

284

Download

991

Sum=1275

Publishing Process of This Article

Item

Count

Browse

366

Download

1017

Sum=1383

Aug 15, 2023 (publication date) through Mar 9, 2026

Times Cited of This Article

Times Cited (50)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Aug 15, 2023; 14(8): 1146-1162
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1146

Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes

Savita Bansal, Archana Burman, Asok Kumar Tripathi

Savita Bansal, Department of Biochemistry, Institute of Home Sciences, University of Delhi, New Delhi 110016, India

Archana Burman, Department of Biochemistry, Institute of Home Economics, University of Delhi, New Delhi 110016, India

Asok Kumar Tripathi, Department of Biochemistry, University College of Medical Sciences, University of Delhi, New Delhi 110095, India

Author contributions: Bansal S frames the review article; all authors have read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Savita Bansal, PhD, Assistant Professor, Department of Biochemistry, Institute of Home Sciences, University of Delhi, Hauz Khas, New Delhi 110016, India. savita.bansal@ihe.du.ac.in

Received: January 29, 2023
Peer-review started: January 29, 2023
First decision: March 1, 2023
Revised: March 21, 2023
Accepted: May 22, 2023
Article in press: May 22, 2023
Published online: August 15, 2023
Processing time: 193 Days and 22.7 Hours

Core Tip

Core tip: Cardiovascular diseases (CVDs) in type 2 diabetes mellitus impose a clinical and an economic burden on the healthcare system. Early diagnosis of diabetes may prevent its progression to complications and decrease its associated comorbidities. The present manuscript reports the clinical relevance of estimating advanced glycation end products (AGEs) in diabetes. The deleterious effects of AGEs include many important biochemical reactions central to the development and progression of cardiovascular complications in diabetes. Therefore, AGEs are one of the important targets for future diagnosis and prevention of diabetes. The epidemiology of CVD in diabetes, AGEs as a crucial mediator of diabetic CVD, and an overview of different strategies for countering the accumulation of AGEs is discussed along with new therapeutic interventions to ameliorate their effects.